Tonix Pharmaceuticals to Present Promising Preclinical Data on TNX-801 Vaccine at Vaccine Congress 2025
Summary
Full Article
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is poised to reveal groundbreaking preclinical data on its TNX-801 vaccine candidate at the Vaccine Congress 2025 in Vienna. The presentation, spearheaded by Dr. Sina Bavari, Executive Vice President of Infectious Disease Research and Development, will highlight the vaccine's protective efficacy against mpox and other orthopoxviruses in animal models, showcasing encouraging outcomes following a single dose.
The TNX-801 platform, a recombinant horsepox virus live vaccine, is engineered to induce long-lasting immune responses, with the adaptability to address other emerging viral threats. Dr. Bavari's presentation will delve into critical findings regarding the vaccine's safety, immunogenicity, and efficacy, alongside outlining the subsequent steps towards the commencement of clinical trials. This advancement represents a pivotal moment in combating mpox, a disease that has experienced a notable resurgence in recent years, highlighting the necessity for innovative vaccine solutions.
For further information on the press release, visit https://ibn.fm/6hDuP.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)